A phase 1 double-blind, placebo controlled, dose-escalation, multi-center therapeutic trial of the safety, immunogenicity, and efficacy of GI-5005; an inactivated recombinant saccharomyces cerevisiae expressing a hepatitis C virus NS3-core fusion protein, in patients with chronic hepatitis C infection
Phase of Trial: Phase I
Latest Information Update: 11 May 2010
At a glance
- Drugs GI 5005 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 11 May 2010 Actual end date (February 2010) added as reported by ClinicalTrials.gov.
- 11 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Aug 2007 Status changed from recruiting to in progress.